Iatreia (Oct 2021)

Chronic lymphocytic Leukemia and deletionof the TP53 gene: Case report and literature review

  • Ucroz-Benavides, Andrea Carolina,
  • Gálvez-Cárdenas, Kenny Mauricio,
  • Ramírez-Gaviria, Gloria Cecilia,
  • Gómez-Lopera, Natalia,
  • Vásquez-Palacio, Gonzalo

DOI
https://doi.org/10.17533/udea.iatreia.115
Journal volume & issue
Vol. 34, no. 4
pp. 370 – 374

Abstract

Read online

Genetic alterations in the TP53 gene are present in 5 to 8% of chronic lymphocytic leukemia (CLL) cases at the time of diagnosis. These cases are typically associated with poor prognosis due to their resistance against standard CLL treatment. In our report a 52-year-old male patient was diagnosed with CLL, CD38 expression and a deletion in the TP53 gene (17p13.1). Upon evaluation post-treatment, minimal residual disease (MDR) was observed, and a haploidentical stem cell transplant was performed. Because of the high risk of relapse, his age, and the absence of comorbidities it was the only curative option to date for CLL. The purpose of this article is to complete a literature review that will give a basis to analyze the clinical case presented, within the framework of the clinical implications, prognosis, and response to treatment in patients with CLL who present with aberrations of the TP53 gene.

Keywords